Inactive Instrument

THES ACQU

RACA

US88339T1034

Biotechnology & Medical Research

Therapeutics Acquisition Corp. has completed an IPO in the amount of $118 million.

July 08, 2020 at 09:30 am IST

Therapeutics Acquisition Corp. has completed an IPO in the amount of $118 million. PriceRange: $10 Discount Per Security: $0.55 Transaction Features: Blank Check Blind Pool Company

Latest news about THES ACQU

Therapeutics Acquisition Corp.(NasdaqCM:RACA) dropped from NASDAQ Composite Index	30/21/30	CI
Point Biopharma Inc. completed the acquisition of Therapeutics Acquisition Corp. from Therapeutics Acquisition Holdings LLC and other shareholders in a reverse merger transaction.	30/21/30	CI
POINT Biopharma Announces First Patients Dosed in Phase 3 Study of PNT2002 for mCRPC	05/21/05	CI
Therapeutics Acquisition : Point Biopharma Phase 3 Trial for Cancer Therapy Doses First Patient Group	04/21/04	MT
Therapeutics Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2021	29/21/29	CI
Merck : Completes Pandion Therapeutics Acquisition	01/21/01	MT
Therapeutics Acquisition : POINT Biopharma To Go Public Via SPAC Combination	15/21/15	MT
Point Biopharma Inc. entered into a non-binding letter of intent to acquire Therapeutics Acquisition Corp. from Therapeutics Acquisition Holdings LLC and other shareholders in a reverse merger transaction.	15/21/15	CI
Therapeutics Acquisition Corp.(NasdaqCM:RACA) added to NASDAQ Composite Index	09/20/09	CI
Therapeutics Acquisition Corp. has completed an IPO in the amount of $118 million.	08/20/08	CI
Certain Class B Common Stock of Therapeutics Acquisition Corp. are subject to a Lock-Up Agreement Ending on 5-JAN-2021.	08/20/08	CI
Therapeutics Acquisition Corp. has filed an IPO in the amount of $100 million.	15/20/15	CI

POINT Biopharma Inc., formerly Therapeutics Acquisition Corp, is a late-stage clinical precision oncology company. The Company focuses on developing and commercializing radiopharmaceuticals for the treatment of cancer. Its pipeline programs include lutetium-177 and actinium-225. The Company's product candidates include PNT2002 and PNT2003 for the treatment of prostate cancer and neuroendocrine tumors. PNT2002 is a prostate-specific membrane antigen (PSMA), targeted radioligand is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC). PNT2002 combines a PSMA-specific ligand, PSMA-I&T, with the beta-emitting radioisotope lutetium-177 (177Lu-PSMA-I&T). PNT2003 is a somatostatin-targeted radioligand in development for the treatment of neuroendocrine tumors. PNT2003 combines a somatostatin-specific radioligand DOTATATE with lutetium-177 (177Lu-DOTATATE).

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+5.66%	11TCr
REGENERON PHARMACEUTICALS, INC.	+11.23%	11TCr
ARGENX SE	-1.98%	2.19TCr
BIONTECH SE	-12.15%	2.23TCr
GENMAB A/S	-5.61%	1.86TCr
WUXI APPTEC CO., LTD.	-36.52%	1.81TCr
BEIGENE, LTD.	-10.09%	1.7TCr
NEUROCRINE BIOSCIENCES, INC.	+3.33%	1.37TCr
SAREPTA THERAPEUTICS, INC.	+36.58%	1.24TCr

Bio Therapeutic Drugs

THES ACQU

Equities

RACA

US88339T1034

Biotechnology & Medical Research

Therapeutics Acquisition Corp. has completed an IPO in the amount of $118 million.

Latest news about THES ACQU

Chart THES ACQU

Company Profile

Sector Bio Therapeutic Drugs